JP2012523458A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523458A5 JP2012523458A5 JP2012506102A JP2012506102A JP2012523458A5 JP 2012523458 A5 JP2012523458 A5 JP 2012523458A5 JP 2012506102 A JP2012506102 A JP 2012506102A JP 2012506102 A JP2012506102 A JP 2012506102A JP 2012523458 A5 JP2012523458 A5 JP 2012523458A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- dimethyl
- composition according
- acid moiety
- enyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 22
- -1 4,8-dimethyl-non-1-enyl group Chemical group 0.000 claims description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 12
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 102000001307 androgen receptors Human genes 0.000 claims description 8
- 108010080146 androgen receptors Proteins 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 102000006478 Protein Phosphatase 2 Human genes 0.000 claims description 3
- 108010058956 Protein Phosphatase 2 Proteins 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16875909P | 2009-04-13 | 2009-04-13 | |
| US61/168,759 | 2009-04-13 | ||
| PCT/US2010/030799 WO2010120711A1 (en) | 2009-04-13 | 2010-04-13 | Protein phosphatase 2a-activating agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012523458A JP2012523458A (ja) | 2012-10-04 |
| JP2012523458A5 true JP2012523458A5 (enExample) | 2013-03-28 |
Family
ID=42981438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506102A Pending JP2012523458A (ja) | 2009-04-13 | 2010-04-13 | タンパク質ホスファターゼ２ａ活性化剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8461362B2 (enExample) |
| EP (1) | EP2419414A4 (enExample) |
| JP (1) | JP2012523458A (enExample) |
| AU (1) | AU2010236655A1 (enExample) |
| CA (1) | CA2758823A1 (enExample) |
| WO (1) | WO2010120711A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2414205T3 (es) * | 2006-06-02 | 2013-07-18 | The Ohio State University Research Foundation | Agentes terapéuticos para el tratamiento de linfoma de células del manto |
| WO2010120711A1 (en) | 2009-04-13 | 2010-10-21 | The Ohio State University Research Foundation | Protein phosphatase 2a-activating agents |
| EP2418948B1 (en) * | 2009-04-17 | 2013-09-04 | The Ohio State University Research Foundation | Antiadhesion agents |
| WO2012074960A2 (en) | 2010-11-29 | 2012-06-07 | The Ohio State University Research Foundation | Fty720-derived anticancer agents |
| US9220706B2 (en) | 2012-06-01 | 2015-12-29 | National Institutes Of Health (Nih) | Inhibition of leukemic stem cells by PP2A activating agents |
| WO2016109825A1 (en) * | 2014-12-31 | 2016-07-07 | Fluidigm Canada Inc. | Structured biological samples for analysis by mass cytometry |
| EP3313819A1 (en) * | 2015-06-23 | 2018-05-02 | Case Western Reserve University | Compositions and methods for treating cancer |
| EP3334725B1 (en) | 2015-08-10 | 2025-04-23 | Dana-Farber Cancer Institute, Inc. | Bromodomain and extra terminal (bet) inhibitor and a protein phosphatase 2a (pp2a) activator for treating bet inhibitor resistant cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2680749A (en) * | 1951-12-01 | 1954-06-08 | Eastman Kodak Co | Water-soluble tocopherol derivatives |
| DE2822324C3 (de) * | 1978-05-22 | 1981-02-26 | Basf Ag, 6700 Ludwigshafen | Herstellung von Vitamin-E-Trockenpulver |
| JPS59222415A (ja) | 1983-05-31 | 1984-12-14 | Kuraray Co Ltd | 免疫調節剤 |
| US4751224A (en) * | 1983-07-21 | 1988-06-14 | Brown University Research Foundation | Treatment of metastasis |
| SK282225B6 (sk) * | 1995-12-28 | 2001-12-03 | Welfide Corporation | Použitie 2-amino-2[2-(4-oktylfenyl)etyl]-propán-1,3-diolu alebo jeho farmaceuticky prijateľnej adičnej soli s kyselinou na výrobu farmaceutického prostriedku |
| US6476004B1 (en) * | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| RU2232758C2 (ru) * | 1998-09-23 | 2004-07-20 | Рисерч Дивелопмент Фаундейшн | Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием |
| US6703384B2 (en) * | 1998-09-23 | 2004-03-09 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| US6770672B1 (en) * | 1998-09-23 | 2004-08-03 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| AU2001236805B2 (en) * | 2000-02-11 | 2005-07-14 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| JP2002121132A (ja) * | 2000-08-09 | 2002-04-23 | Showa Denko Kk | 発がん抑制剤および発がん抑制方法 |
| CA2455547A1 (en) * | 2001-07-27 | 2003-02-13 | University Of Rochester | Use of vitamin e succinate and antiandrogen combination |
| US6858227B1 (en) * | 2001-11-21 | 2005-02-22 | Sonus Pharmaceuticals, Inc. | Vitamin E conjugates |
| US20050215531A1 (en) * | 2002-05-16 | 2005-09-29 | Thomas Baumruker | Use of edg receptor binding agents in cancer |
| JP4861177B2 (ja) * | 2003-09-12 | 2012-01-25 | ニューロノバ エービー | 神経系の障害の処置 |
| CA2583087C (en) * | 2003-09-19 | 2012-07-10 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| CN101346346B (zh) * | 2005-12-15 | 2012-08-22 | 田边三菱制药株式会社 | 胺化合物及其医药用途 |
| US20080009545A1 (en) * | 2006-02-21 | 2008-01-10 | The Ohio State University Research Foundation | Anticancer agents |
| ES2414205T3 (es) | 2006-06-02 | 2013-07-18 | The Ohio State University Research Foundation | Agentes terapéuticos para el tratamiento de linfoma de células del manto |
| CA2660880C (en) | 2006-08-17 | 2015-10-13 | Betty C. Soliven | Treatment of inflammatory diseases |
| NZ575920A (en) * | 2006-09-15 | 2012-08-31 | Stephen John Ralph | Pro-oxidant anti-cancer compounds |
| JP4481316B2 (ja) * | 2007-01-09 | 2010-06-16 | 株式会社エヌ・ティ・ティ・ドコモ | ユーザ装置および送信方法 |
| BRPI0813683A2 (pt) * | 2007-06-14 | 2019-09-24 | Mitsubishi Tanabe Pharma Corp | composto amina e uso farmacêutico do mesmo |
| WO2010042998A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1p receptors modulators |
| WO2010120711A1 (en) | 2009-04-13 | 2010-10-21 | The Ohio State University Research Foundation | Protein phosphatase 2a-activating agents |
| EP2418948B1 (en) | 2009-04-17 | 2013-09-04 | The Ohio State University Research Foundation | Antiadhesion agents |
-
2010
- 2010-04-13 WO PCT/US2010/030799 patent/WO2010120711A1/en not_active Ceased
- 2010-04-13 CA CA2758823A patent/CA2758823A1/en not_active Abandoned
- 2010-04-13 AU AU2010236655A patent/AU2010236655A1/en not_active Abandoned
- 2010-04-13 US US12/758,858 patent/US8461362B2/en not_active Expired - Fee Related
- 2010-04-13 JP JP2012506102A patent/JP2012523458A/ja active Pending
- 2010-04-13 EP EP10764981.6A patent/EP2419414A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012523458A5 (enExample) | ||
| CY1124882T1 (el) | Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn | |
| JP2010077141A5 (enExample) | ||
| JP2012144574A5 (enExample) | ||
| EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| JP2013542261A5 (enExample) | ||
| MX2009004475A (es) | Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma. | |
| JP2013510120A5 (enExample) | ||
| BR112016011949A2 (pt) | Composto, composição farmacêutica, e, uso dos mesmos | |
| JP2009530398A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| BRPI0510414A (pt) | uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos | |
| MX2010010647A (es) | Proceso para preparar formulaciones de dabigatran para administracion oral. | |
| MX377255B (es) | Lipidos y composiciones de lipidos para el suministro de agentes activos. | |
| JP2016515561A5 (enExample) | ||
| JP2010265321A5 (enExample) | ||
| JP2013507423A5 (enExample) | ||
| JP2014513123A5 (enExample) | ||
| MX2010007375A (es) | Nuevos derivados de lupano. | |
| JP2014515406A5 (enExample) | ||
| JP2009102342A5 (enExample) | ||
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| UA105229C2 (uk) | Фармацевтичний склад | |
| JP2015509075A5 (enExample) |